BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Healthcare Master Fun Broadfin sold 2,000,000 shares of BioDelivery Sciences International stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $5.00, for a total value of $10,000,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of BDSI traded down $0.17 during mid-day trading on Monday, reaching $4.81. The company had a trading volume of 833,098 shares, compared to its average volume of 914,167. The company has a quick ratio of 2.82, a current ratio of 3.07 and a debt-to-equity ratio of 1.74. BioDelivery Sciences International, Inc. has a 52 week low of $1.70 and a 52 week high of $5.37. The stock has a market cap of $350.49 million, a P/E ratio of -6.59 and a beta of 0.46.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). The firm had revenue of $18.03 million for the quarter, compared to analysts’ expectations of $16.15 million. BioDelivery Sciences International had a negative return on equity of 79.59% and a negative net margin of 60.87%. On average, equities analysts anticipate that BioDelivery Sciences International, Inc. will post -0.19 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. grew its position in shares of BioDelivery Sciences International by 56.3% during the fourth quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after purchasing an additional 3,943 shares in the last quarter. Squarepoint Ops LLC purchased a new position in BioDelivery Sciences International in the fourth quarter worth $147,000. Raymond James & Associates grew its holdings in BioDelivery Sciences International by 14.9% in the fourth quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock worth $171,000 after purchasing an additional 6,000 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in BioDelivery Sciences International in the third quarter worth $255,000. Finally, Virtu Financial LLC purchased a new position in BioDelivery Sciences International in the first quarter worth $300,000. 56.89% of the stock is currently owned by institutional investors and hedge funds.

BDSI has been the subject of several research analyst reports. Cantor Fitzgerald set a $8.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Friday, April 5th. Zacks Investment Research downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. SunTrust Banks began coverage on BioDelivery Sciences International in a report on Tuesday, March 19th. They set a “buy” rating and a $7.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of BioDelivery Sciences International in a report on Friday, March 15th. Finally, BidaskClub raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. BioDelivery Sciences International has an average rating of “Buy” and a consensus target price of $5.79.

TRADEMARK VIOLATION NOTICE: “BioDelivery Sciences International, Inc. (BDSI) Director Sells $10,000,000.00 in Stock” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2019/04/15/biodelivery-sciences-international-inc-bdsi-director-sells-10000000-00-in-stock.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Read More: Why do companies issue convertible shares?

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.